Summary
Antibiotics are administered to cystic fibrosis patients for chronic endobronchial infection complicated by frequent exacerbations. Agents active against Staphylococcus aureus, Pseudomonas aeruginosa or both are administered. Serum antibiotic concentrations were measured in cystic fibrosis patients in an effort to optimise antibiotic dose and frequency. This led to the observation that cystic fibrosis subjects had (in general) a larger Vd and increased total body clearance of β-lactams and aminoglycosides than non-cystic fibrosis subjects. The larger Vd is mainly due to the increased amount of lean body mass per kg bodyweight, although increased tissue binding may also account for part of this. The increased total body clearance of β-lactams appears to be due to increased renal elimination, particularly tubular secretion. Decreased tubular reabsorption and increased non-renal clearance contribute to the increased total body clearance of metabolised β-lactams and aminoglycosides. However, the lack of concomitant controls in many studies make these generalisations tentative.
The result of the apparent cystic fibrosis-specific differences is lower peak serum antibiotic concentrations, a smaller AUC, and a shorter elimination half-life than non-cystic fibrosis subjects. Since sputum (and bronchial mucosal) concentration is dependent on the peak serum concentration (and AUC), cystic fibrosis subjects require larger doses of most antibiotics more frequently. Newer quinolones may be an exception. Studies comparing the efficacy and safety of larger and more frequent antibiotic doses to conventional therapy are not available. Although it appears logical to mimic serum antibiotic concentrations found in non-cystic fibrosis subjects, the lack of information on the ideal sputum concentration versus time curve should temper our enthusiasm for cystic fibrosis-specific dosage regimens.
Similar content being viewed by others
References
Adelman M, Evans E, Schentag JJ. Two-compartment comparison of gentamicin and tobramycin in normal volunteers. Antimicrobial Agents and Chemotherapy 22: 800–804, 1982
Arvidsson A, Alvan G, Strandvik B. Difference in renal handling of cefsulodin between patients with cystic fibrosis and normal subjects. Acta Paediatrica Scandinavica 72: 293–294, 1983
Barry AL, Jones RN, Thornsberry C, Ayers LW, Gerlach EH, et al. Antibacterial activities of ciprofloxacin, norfloxacin, oxolinic acid, cinoxacin, and nalidixic acid. Antimicrobial Agents and Chemotherapy 25: 633–637, 1984
Bauer LA, Blouin RA. Influence of age on tobramycin pharmacokinetics in patients with normal renal function. Antimicrobial Agents and Chemotherapy 20: 587–589, 1981
Bauer LA, Piecoro Jr JJ, Wilson HD, Blouin RA. Gentamicin and tobramycin pharmacokinetics in patients with cystic fibrosis. Clinical Pharmacy 2: 262–264, 1983
Beaudry PH, Marks MI, McDougall D, Desmond K, Rangel R. Is anti-Pseudomonas therapy warranted in acute respiratory exacerbations in children with cystic fibrosis? Journal of Pediatrics 97: 144–147, 1980
Bergan T. Overview of acylureidopenicillin pharmacokinetics. Scandinavian Journal of Infectious Diseases (Suppl. 29): 33–48, 1981
Bergan T, Michaisen H. Pharmacokinetics of azlocillin in children with cystic fibrosis. Arzneimittel-Forschung 29: 1955–1957, 1979
Bergan T, Thorsteinsson SB, Steingrimsson O. Dose-dependent pharmacokinetics of azlocillin compared to mezlocillin. Chemotherapy 28: 160–170, 1982
Bergan T, Williams JD. Dose dependence of piperacillin pharmacokinetics. Chemotherapy 28: 153–159, 1982
Berry PL, Kearns GL, Brown RD, Ritschel WA, Thompson GA, et al. Gentamicin disposition in children with chronic renal failure. Pediatric Pharmacology 2: 257–273, 1982
Blumer JL, Stern RC, Klinger JD, Yamashita TS, Meyers CM, et al. Ceftazidime therapy in patients with cystic fibrosis and multiple-drug-resistant Pseudomonas. American Journal of Medicine 79 (Suppl. 2A): 37–46, 1985
Blumer JL, Stern RC, Yamashita TS, Myers CM, Reed MD. Cephalosporin therapeutics in cystic fibrosis. Journal of Pediatrics 108: 854–860, 1986
Bodey GP, Yeo E, Ho DH, Rolston K, LeBlanc B. Clinical pharmacology of timentin (ticarcillin and clavulanic acid). Clinical Pharmacology and Therapeutics 37: 134–149, 1985
Bosso JA, Saxon BA, Herbst JJ, Matsen JM. Azlocillin pharmacokinetics in patients with cystic fibrosis. Antimicrobial Agents and Chemotherapy 25: 630–632, 1984
Bradbear RA, Shepherd RW, Grice J, O’Toole J, Roberts RK. Cimetidine use in children with cystic fibrosis: inhibition of hepatic drug metabolism. Journal of Pediatrics 100: 325–327, 1982
Caplan DB, Buchanan CN. Treatment of lower respiratory tract infections due to Pseudomonas aeruginosa in patients with cystic fibrosis. Reviews of Infectious Diseases 6 (Suppl. 3): S705–S710, 1984
Colaizzi PA, Polk RE, Poynor WJ, Raffalovich AC, Cefali EA, et al. Comparative pharmacokinetics of azlocillin and piperacillin in normal adults. Antimicrobial Agents and Chemotherapy 29: 938–940, 1986
Davies BE, Humphrey MJ, Langly PF, Lees L, Legg B, et al. Pharmacokinetics of ticarcillin in man. Clinical Pharmacology 23: 167–172, 1982
Davis RL, Williams-Warren J, Weber A, Koup JR, Stempel D, et al. Pharmacokinetics of ciprofloxacin in adult males with and without cystic fibrosis. Antimicrobial Agents and Chemotherapy, in press, 1987
de Groot R, Hack B, Weber A, Chaffin D, Ramsey B, et al. Pharmacokinetics of ticarcillin in patients with cystic fibrosis: a prospective controlled study. Submitted for publication, 1987.
Drusano GL, Plaisance KI, Forrest A, Standiford HC. Dose ranging study and constant infusion evaluation of ciprofloxacin. Antimicrobial Agents and Chemotherapy 30: 440–443, 1986
Evans MAL, Wilson P, Leung T, Williams JD. Pharmacokinetics of piperacillin following intravenous administration. Journal of Antimicrobial Chemotherapy 4: 255–261, 1978
Finkelstein E, Hall K. Aminoglycoside clearance in patients with cystic fibrosis. Journal of Pediatrics 94: 163–164, 1979
Fishman AP. State of the art: chronic cor pulmonale. American Review of Respiratory Diseases 114: 775–794, 1976
Forsyth JS, Moreland TA, Rylance GW. The effect of fever on antipyrine metabolism in children. British Journal of Clinical Pharmacology 13: 811–815, 1982
Fu KP, Neu HC. Piperacillin, a new penicillin active against many bacteria resistant to other penicillins. Antimicrobial Agents and Chemotherapy 13: 358–367, 1978
Gibaldi M, Koup JR. Pharmacokinetic concepts: drug binding, apparent volume of distribution and clearance. European Journal of Clinical Pharmacology 20: 299–305, 1981
Giron JA, Meyers BR, Hirschman SZ. Biliary concentrations of piperacillin in patients undergoing cholecystectomy. Antimicrobial Agents and Chemotherapy 19: 309–311, 1981
Glupczynski Y, Crokaert F, van der Linden MP, Yourassowsky E. Activity of cefsulodin against methicillin-resistant Staphylococcus aureus. Current Therapeutic Research 37: 467–471, 1985
Gold R, Overmeyer A, Knie B, Fleming PC, Levison H. Controlled trial of ceftazidime vs ticarcillin and tobramycin in the treatment of acute respiratory exacerbations in patients with cystic fibrosis. Pediatric Infectious Disease 4: 172–177, 1985
Goldmann DA, Syriopoulou GPh, Semple AM. Correlation of netilmicin agar dilution and disk diffusion susceptibilities. Antimicrobial Agents and Chemotherapy 12: 288–289, 1977
Gonzalez MA, Moranchel AH, Duran S, Pichardo A, Magana JL, et al. Multiple-dose pharmacokinetics of ciprofloxacin administered intravenously to normal volunteers. Antimicrobial Agents and Chemotherapy 28: 235–239, 1985
Gouyette A, Kitzis MD, Guibert J, Acar JF. Pharmacokinetics and bioavailability of intramuscular preparations of ticarcillin. Journal of Antimicrobial Chemotherapy 10: 419–425, 1982
Granneman GR, Sennello LT, Sonders RC, Wynne B, Thomas EW. Cefsulodin kinetics in healthy subjects after intramuscular and intravenous injection. Clinical Pharmacology and Therapeutics 31: 95–103, 1982
Hamilton-Miller JMT, Gooding A, Brumfitt W. Resistance to trimethoprim in 1978–79 compared with 1973–75. Journal of Clinical Pathology 34: 439–442, 1981
Harding SM, Monro AJ, Thornton JE, Ayrton J, Hogg MIJ. The comparative pharmacokinetics of ceftazidime and cefotaxime in healthy volunteers. Journal of Antimicrobial Chemotherapy 8 (Suppl. B): 263–272, 1981
Hoffken G, Lode H, Prinzing C, Borner K, Koeppe P. Pharmacokinetics of ciprofloxacin after oral and parenteral administration. Antimicrobial Agents and Chemotherapy 27: 375–379, 1985
Hoogkamp-Korstanje JAA, van der Laag J. Piperacillin and tobramycin in the treatment of Pseudomonas lung infections in cystic fibrosis. Journal of Antimicrobial Chemotherapy 12: 175–183, 1983
Hoppu K, Arjomaa P. Difference in trimethoprim pharmacokinetics between children and adults. Chemotherapy 30: 283–287, 1984
Horrevorts AM, Degener JE, Dzoljic-Danilovic G, Michel MF, Kerrebijn KF, et al. Pharmacokinetics of tobramycin in patients with cystic fibrosis. Chest 88: 260–264, 1985
Hsu M-C, Aguila HA, Schmidt VL, Munzenberger PJ, Kauffman RE, et al. Individualization of tobramycin dosage in patients with cystic fibrosis. Pediatric Infectious Disease 3: 526–529, 1984
Jackson GG, Riff LJ. Pseudomonas bacteremia: pharmacologic and other bases for failure of treatment with gentamicin. Journal of Infectious Disease 124 (S): S185–S191, 1971
Jacobs RF, Trang JM, Kearns GL, Warren RH, Brown AL, et al. Ticarcillin/clavulanic acid pharmacokinetics in children and young adults with cystic fibrosis. Journal of Pediatrics 106: 1001–1007, 1985
Jusko WJ, Mosovich LL, Gerbracht LM, Mattar ME, Yaffe SJ. Enhanced renal excretion of dicloxacillin in patients with cystic fibrosis. Pediatrics 55: 1038–1044, 1975
Kearns GL, Hilman BC, Wilson JT. Dosing implications of altered gentamicin disposition in patients with cystic fibrosis. Journal of Pediatrics 100: 312–318, 1982
Kelly HW, Lovato C. Antibiotic use in cystic fibrosis. Drug Intelligence and Clinical Pharmacy 18: 772–783, 1984
Kelly HW, Menendez R, Fan L, Murphy Sh. Pharmacokinetics of tobramycin in cystic fibrosis. Journal of Pediatrics 100: 318–321, 1982
Kercsmar CM, Stern RC, Reed MD, Myers CM, Murdell D, et al. Journal of Antimicrobial Chemotherapy 12 (Suppl. A): 289–295, 1983
King CH, Creger RJ, Ellner JJ. Pharmacokinetics of tobramycin and gentamicin in abusers of intravenous drugs. Antimicrobial Agents and Chemotherapy 27: 285–290, 1985
Kirby WMM, Clarke JT, Libke RD, Regamey Cl. Clinical pharmacology of amikacin and kanamycin. Journal of Infectious Diseases 134 (S): S312–S315, 1976
Kondo M, Tsuchiya K. Comparative in vitro activities of cefsulodin, sulbenicillin, and gentamicin against Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy 14: 151–153, 1978
Korsager S. Administration of gentamicin to obese patients. International Journal of Clinical Pharmacology, Therapy and Toxicology 18: 549–553, 1980
Kramer WG, Cleary T, Frankel LS, Kohl S, Pickering LK. Multiple-dose amikacin kinetics in pediatric oncology patients. Clinical Pharmacology and Therapeutics 26: 635–640, 1979
Laskin OL, Longstreth AJ, Smith CR, Lietman PS. Netilmicin and gentamicin multidose kinetics in normal subjects. Clinical Pharmacology and Therapeutics 34: 644–650, 1983
LeBel M, Bergeron MG, Vallée F, Fiset C, Chassé G, et al. Pharmacokinetics and pharmacodynamics of ciprofloxacin in cystic fibrosis patients. Antimicrobial Agents and Chemotherapy 30: 260–266, 1986
Leeder JS, Spino M, Isles AF, Tesoro AM, Gold R, et al. Ceftazidime disposition in acute and stable cystic fibrosis. Clinical Pharmacology and Therapeutics 36: 355–362, 1984
Leroy A, Humbert G, Fillastre JP. Pharmacokinetics of azlocillin in healthy subjects. Scandinavian Journal of Infectious Disease (Suppl. 29): 49–51, 1981
Levy J, Smith AL, Kenny MA, Ramsey B, Schoenknecht FD. Bioactivity of gentamicin in purulent sputum from patients with cystic fibrosis or bronchiectasis: comparison with activity in serum. Journal of Infectious Diseases 148: 1069–1076, 1983
Levy J, Smith AL, Koup JR, Williams-Warren J, Ramsey B. Disposition of tobramycin in patients with cystic fibrosis: a prospective controlled study. Journal of Pediatrics 105: 117–124, 1984
Libke RD, Clarke JT, Ralph ED, Luthy RP, Kirby WMM. Ticarcillin vs carbenicillin: clinical pharmacokinetics. Clinical Pharmacology and Therapeutics 17: 441–446, 1975
Livermore DM, Williams RJ, Williams JD. In vitro activity of ceftazidime against Pseudomonas aeruginosa: and its stability to pseudomonal β-lactamases. Journal of Antimicrobial Chemotherapy 8 (Suppl. B): 163–167, 1981
Lode H, Niestrath U, Koeppe P, Langmaack H. Azlocillin und mezlocillin: zwei neue semisynthetische acylureidopenicilline. Infection 5: 163–169, 1977
MacDonald NE, Anas NG, Peterson RG, Schwartz RH, Brooks JG, et al. Renal clearance of gentamicin in cystic fibrosis. Journal of Pediatrics 103: 985–990, 1983
Malmborg A-S, Alfredsson H, Kusoffsky E, Strandvik B. Azlocillin and gentamicin in respiratory tract infections with Pseudomonas aeruginosa in patients with cystic fibrosis. Scandinavian Journal of Infectious Diseases (Suppl. 29): 64–69, 1981
Marks MI. The pathogenesis and treatment of pulmonary infections in patients with cystic fibrosis. Journal of Pediatrics 98: 173–179, 1981
Marlin GE, Burgess KR, Burgoyne J, Funnell GR, Guinness MDG. Penetration of piperacillin into bronchial mucosa and sputum. Thorax 36: 774–780, 1981
McLaughlin IJ, Matthews Jr WJ, Strieder DJ, Sullivan B, Taneja A, et al. Clinical and bacteriological responses to three antibiotic regimens for acute exacerbations of cystic fibrosis: ticarcillin-tobramycin, azlocillin-tobramycin, and azlocillin-placebo. Journal of Infectious Diseases 147: 559–567, 1983
McNeill WF, John Jr JF, Twitty JA. Aminoglycoside resistance in Pseudomonas aeruginosa isolated from cystic fibrosis patients. American Journal of Clinical Pathology 81: 741–747, 1984
Mendelman PM, Smith AL, Levy J, Weber A, Ramsey B, et al. Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum. American Review of Respiratory Diseases 132: 761–765, 1985
Meyers BR, Hirschman SZ, Strougo L, Srulevitch E. Comparative study of piperacillin, ticarcillin, and carbenicillin pharmacokinetics. Antimicrobial Agents and Chemotherapy 17: 608–611, 1980
Michaisen H, Bergan T. Pharmacokinetics of netilmicin in children with and without cystic fibrosis. Antimicrobial Agents and Chemotherapy 19: 1029–1031, 1981
Neu HC. Tobramycin: an overview. Journal of Infectious Disease 134 (S): S3–S19, 1976
Neu HC, Garvey GJ. Comparative in vitro activity and clinical pharmacology of ticarcillin and carbenicillin. Antimicrobial Agents and Chemotherapy 8: 457–462, 1975
Noone P, Parsons TMC, Pattison JR, Slack NCB, Garfield-Davies D, et al. Experience in monitoring gentamicin therapy during treatment of serious gram-negative sepsis. British Medical Journal 1: 477–481, 1974
Norrby SR, Alestig K, Bjornegard B, Burman LA, Ferber F, et al. Urinary recovery of N-formimidoyl thienamycin (MK0787) as affected by coadministration of N-formimidoyl thienamycin dehydropeptidase inhibitors. Antimicrobial Agents and Chemotherapy 23: 300–307, 1983a
Norrby SR, Alestig K, Ferber F, Huber JL, Jones KH, et al. Pharmacokinetics and tolerance of N-formimidoyl thienamycin (MK0787) in humans. Antimicrobial Agents and Chemotherapy 23: 293–299, 1983b
Padoan R, Brienza A, Crossignani RM, Lodi G, Giunta A, et al. Ceftazidime in treatment of acute pulmonary exacerbations in patients with cystic fibrosis. Journal of Pediatrics 103: 320–324, 1983
Parry MF, Neu HC. Comparison and evaluation of ticarcillin and carbenicillin using disk diffusion methods. Antimicrobial Agents and Chemotherapy 9: 625–632, 1976a
Parry MF, Neu HC. Tobramycin and ticarcillin therapy for exacerbations of pulmonary disease in patients with cystic fibrosis. Journal of Infectious Diseases 134 (S): S194–S197, 1976b
Parry MF, Neu HC, Merlino M, Gaerlan PF, Ores CN, et al. Treatment of pulmonary infections in patients with cystic fibrosis: a comparative study of ticarcillin and gentamicin. Journal of Pediatrics 90: 144–148, 1977
Pechere J-C, Dugal R. Clinical pharmacokinetics of aminoglycoside antibiotics. Clinical Pharmacokinetics 4: 170–199, 1979
Pedersen SS, Pressler T, Noiby N, Bentzon MW, Koch C. Imipenem/cilastatin treatment of multiresistant Pseudomonas aeruginosa lung infection in cystic fibrosis. Journal of Antimicrobial Chemotherapy 16: 629–635, 1985
Pelton SI, Shurin PA, Klein JO, Finland M. Quantitative inhibition of Haemophilus influenzae by trimethoprim/sulfamethoxazole. Antimicrobial Agents and Chemotherapy 12: 649–654, 1977
Pennington JE. Kinetics of penetration and clearance of antibiotics in respiratory secretions. In Kirkpatrick & Reynolds (Eds). Immunologic and infectious reactions in the lung, Vol. 1, pp. 355–374, Marcel Dekker, New York, 1976
Permin H, Koch C, Hoiby N, Christensen HO, Moller AF, et al. Ceftazidime treatment of chronic Pseudomonas aeruginosa respiratory tract infection in cystic fibrosis. Journal of Antimicrobial Chemotherapy 12 (Suppl. A): 313–323, 1983
Prince AS, Neu HC. Use of piperacillin, a semisynthetic penicillin, in the therapy of acute exacerbations of pulmonary disease in patients with cystic fibrosis. Journal of Pediatrics 97: 148–151, 1980
Reed MD, Stern RC, Bertino Jr JS, Myers CM, Yamashita TS, et al. Dosing implications of rapid elimination of trimethoprim-sulfamethoxazole in patients with cystic fibrosis. Journal of Pediatrics 104: 303–307, 1984a
Reed MD, Stern RC, O’Brien CA, Yamashita TS, Myers CM, et al. Pharmacokinetics of imipenem and cilastatin in patients with cystic fibrosis. Antimicrobial Agents and Chemotherapy 27: 583–588, 1985
Reed MD, Stern RC, Yamashita TS, Ackers I, Myers CM, et al. Single-dose pharmacokinetics of cefsulodin in patients with cystic fibrosis. Antimicrobial Agents and Chemotherapy 25: 579–581, 1984b
Richmond MH. The semi-synthetic thienamycin derivative MK0787 and its properties with respect to a range of β-lactamases from clinically relevant bacterial species. Journal of Antimicrobial Chemotherapy 7: 279–285, 1981
Romagnoli MF, Fu KP, Neu HC. The antibacterial activity of thienamycin against multiresistant bacteria: comparison with β-lactamase stable compounds. Journal of Antimicrobial Chemotherapy 6: 601–606, 1980
Rosenthal A, Button LN, Khaw KT. Blood volume changes in patients with cystic fibrosis. Pediatrics 59: 588–594, 1977
Rotschafer JC, Morlock C, Strand L, Crossley K. Comparison of radio-immunoassay and enzyme immunoassay methods in determining gentamicin pharmacokinetic parameters and dosages. Antimicrobial Agents and Chemotherapy 22: 648–651, 1982
Saenger P, Rifkind AB, Pareira J. Effect of glucocorticoids and ACTH on antipyrine clearance in children. Clinical Pharmacology and Therapeutics 23: 692–696, 1978
Schwartz DE, Vetter W, Engbert G. Trimethoprim metabolites in rat, dog and man: qualitative and quantitative studies. Arzneimittel-Forschung 20: 1867–1871, 1970
Scribner RK, Marks MI, Weber AH, Tarpay MM, Welch DF. Activities of various β-lactams and aminoglycosides, alone and in combination, against isolates of Pseudomonas aeruginosa from patients with cystic fibrosis. Antimicrobial Agents and Chemotherapy 21: 939–943, 1982
Siber GR, Gorham CC, Ericson JF, Smith AL. Pharmacokinetics of intravenous trimethoprim-sulfamethoxazole in children and adults with normal and impaired renal function. Reviews of Infectious Diseases 4: 566–578, 1982
Smith AL, Opheim KE. Comparison of methods for clinical quantitation of antibiotics. In Remington & Swartz (Eds). Current clinical topics in infectious diseases, pp. 333–357, McGraw-Hill, New York, 1983
Sobonya RE, Taussig LM. Quantitative aspects of lung pathology in cystic fibrosis. American Review of Respiratory Diseases 134: 290–295, 1986
Spino M, Chai RP, Isles AF, Balfe JW, Brown RG, et al. Assessment of glomerular filtration rate and effective renal plasma flow in cystic fibrosis. Journal of Pediatrics 107: 64–70, 1985
Spino M, Chai RP, Isles AF, Thiessen JJ, Tesore A, et al. Cloxacillin absorption and disposition in cystic fibrosis. Journal of Pediatrics 105: 829–835, 1984
Strandvik B, Malmborg A-S, Alfredson H, Ericsson A. Clinical results and pharmacokinetics of ceftazidime treatment in patients with cystic fibrosis. Journal of Antimicrobial Chemotherapy 12 (Suppl. A): 283–287, 1983
Tausk F, Stratton CW. Effect of clavulanic acid on the activity of ticarcillin against Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy 30: 584–589, 1986
Thirumoorthi MC, Asmar BI, Buckley JA, Bollinger RG, Kauffman RE, et al. Pharmacokinetics of intravenously administered piperacillin in preadolescent children. Pediatric Pharmacology and Therapeutics 102: 941–946, 1983
Tjandramaga TB, Mullie A, Verbesselt R, De Schepper PJ, Verbist L. Piperacillin: human pharmacokinetics after intravenous and intramuscular administration. Antimicrobial Agents and Chemotherapy 14: 829–837, 1978
Verbist L. Comparison of the activities of the new ureidopenicillins piperacillin, mezlocillin, azlocillin, and Bay k 4999 against gram-negative organisms. Antimicrobial Agents and Chemotherapy 16: 115–119, 1979
Vogelstein B, Kowarski A, Lietman PS. The pharmacokinetics of amikacin in children. Journal of Pediatrics 91: 333–339, 1977
Wald ER, Standiford HC, Tatem BA, Calia FM, Hornick RB. BL-P1654, ticarcillin, and carbenicillin: in vitro comparison alone and in combination with gentamicin against Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy 7: 336–340, 1975
Weber AM, Roy CC, Morin CL, Lasalle R. Malabsorption of bile acids in children with cystic fibrosis. New England Journal of Medicine 289: 1001–1005, 1973
Welling PG, Craig WA, Amidon GI, Kunin CM. Pharmacokinetics of trimethoprim and sulfamethoxazole in normal subjects and in patients with renal failure. Journal of Infectious Diseases 128 (S): 556–566, 1973
Wenk M, Spring P, Vozeh S, Follath F. Multicompartment pharmacokinetics of netilmicin. European Journal of Clinical Pharmacology 16: 331–334, 1979
Wilson CB, Koup JR, Opheim KE, Adelman LA, Levy J, et al. Piperacillin pharmacokinetics in pediatric patients. Antimicrobial Agents and Chemotherapy 22: 442–447, 1982
Wilson TW, Mahon WA, Inaba T, Johnson GE, Kadar D. Elimination of tritiated gentamicin in normal human subjects and in patients with severely impaired renal function. Clinical Pharmacology and Therapeutics 14: 815–822, 1973
Wirth K, Schomerus M, Hengstmann HJ. Zur pharmacokinetik von azlocillin, einem neuen halbsynthetischen breitspektrumantibiotikum. Infection 4: 25–30, 1976
Woolf RA, Koup JR, Smith AL, Hilman BC, Goldmann D, et al. Pharmacokinetics of high-dose azlocillin sodium in patients with cystic fibrosis. Clinical Pharmacy 4: 664–669, 1985
Yaffe SJ, Gerbracht LM, Mosovich LL, Mattar ME, Danish M, et al. Pharmacokinetics of methicillin in patients with cystic fibrosis. Journal of Infectious Diseases 135: 828–831, 1977
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
de Groot, R., Smith, A.L. Antibiotic Pharmacokinetics in Cystic Fibrosis. Clin-Pharmacokinet 13, 228–253 (1987). https://doi.org/10.2165/00003088-198713040-00002
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003088-198713040-00002